tetano
Editor, Senior Moderator
Rev Assoc Med Bras (1992)
. 2023 Mar 3;69(2):257-261.
doi: 10.1590/1806-9282.20220955. eCollection 2023.
Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil
Gúbio Soares Campos[SUP] 1 [/SUP], Marta Giovanetti[SUP] 2 [/SUP], Laíse de Moraes[SUP] 3 [/SUP], Helena Souza da Hora[SUP] 1 [/SUP], Antônio Carlos de Albuquerque Bandeira[SUP] 4 [/SUP], Keila Veronica Oliveira Motta De Alcantara[SUP] 1 [/SUP], Silvia Ines Sardi[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: Genome sequencing has been proved to be an excellent tool to monitor the molecular epidemiology of the disease caused by severe acute respiratory syndrome coronavirus 2, i.e., coronavirus disease 2019. Some reports of infected, vaccinated individuals have aroused great interest because they are primarily being infected with circulating variants of concern. To investigate the cases of infected, vaccinated individuals in Salvador, Bahia, Brazil, we performed genomic monitoring to estimate the magnitude of the different variants of concern in these cases.
Methods: Nasopharyngeal swabs from infected (symptomatic and asymptomatic), vaccinated or unvaccinated individuals (n=29), and quantitative reverse transcription polymerase chain reaction cycle threshold value (Ct values) of ≤30 were subjected to viral sequencing using nanopore technology.
Results: Our analysis revealed that the Omicron variant was found in 99% of cases and the Delta variant was found in only one case. Infected, fully vaccinated patients have a favorable clinical prognosis; however, within the community, they become viral carriers with the aggravating factor of viral dissemination of variants of concern not neutralized by the currently available vaccines.
Conclusion: It is important to acknowledge the limitations of these vaccines and to develop new vaccines to emergent variants of concern, as is the case of influenza vaccine; going through new doses of the same coronavirus vaccines is "more of the same."
. 2023 Mar 3;69(2):257-261.
doi: 10.1590/1806-9282.20220955. eCollection 2023.
Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil
Gúbio Soares Campos[SUP] 1 [/SUP], Marta Giovanetti[SUP] 2 [/SUP], Laíse de Moraes[SUP] 3 [/SUP], Helena Souza da Hora[SUP] 1 [/SUP], Antônio Carlos de Albuquerque Bandeira[SUP] 4 [/SUP], Keila Veronica Oliveira Motta De Alcantara[SUP] 1 [/SUP], Silvia Ines Sardi[SUP] 1 [/SUP]
Affiliations
- PMID: 36888766
- DOI: 10.1590/1806-9282.20220955
Abstract
Objective: Genome sequencing has been proved to be an excellent tool to monitor the molecular epidemiology of the disease caused by severe acute respiratory syndrome coronavirus 2, i.e., coronavirus disease 2019. Some reports of infected, vaccinated individuals have aroused great interest because they are primarily being infected with circulating variants of concern. To investigate the cases of infected, vaccinated individuals in Salvador, Bahia, Brazil, we performed genomic monitoring to estimate the magnitude of the different variants of concern in these cases.
Methods: Nasopharyngeal swabs from infected (symptomatic and asymptomatic), vaccinated or unvaccinated individuals (n=29), and quantitative reverse transcription polymerase chain reaction cycle threshold value (Ct values) of ≤30 were subjected to viral sequencing using nanopore technology.
Results: Our analysis revealed that the Omicron variant was found in 99% of cases and the Delta variant was found in only one case. Infected, fully vaccinated patients have a favorable clinical prognosis; however, within the community, they become viral carriers with the aggravating factor of viral dissemination of variants of concern not neutralized by the currently available vaccines.
Conclusion: It is important to acknowledge the limitations of these vaccines and to develop new vaccines to emergent variants of concern, as is the case of influenza vaccine; going through new doses of the same coronavirus vaccines is "more of the same."